[SCHEDULE 13G/A] Travere Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

The Vanguard Group filed Amendment 9 to its Schedule 13G on Travere Therapeutics (TVTX) covering holdings as of 30 Jun 2025.

• Beneficial ownership: 5,994,283 common shares, representing 6.74 % of the outstanding class.
• Voting power: 0 shares sole, 107,100 shares shared.
• Dispositive power: 5,806,026 shares sole, 188,257 shares shared.
• Filed pursuant to Rule 13d-1(b); Vanguard is classified as an investment adviser (IA).
• Certification states shares were acquired in the ordinary course, with no intent to influence control.

The disclosure confirms Vanguard remains a passive, >5 % institutional holder in Travere, signalling continued interest without control ambitions.

Insights

Securities Analyst

TL;DR Vanguard’s 6.7 % stake affirms institutional support but provides no new control or strategic signal.

Vanguard retains nearly 6 M shares, solidifying its position as a top shareholder. The absence of sole voting power indicates a purely passive posture; dispositive authority remains strong, giving Vanguard flexibility to adjust exposure. While the ownership level exceeds the 5 % reporting threshold, it is not large enough to exert control, and the certification confirms no activist intent. For investors, a large passive holder can improve liquidity and enhance governance scrutiny, but it does not directly alter Travere’s strategic trajectory.

Corporate Governance Expert

TL;DR Filing is routine; passive stake offers governance oversight but limited immediate impact.

The amendment updates share counts and complies with Section 13 reporting requirements. Vanguard’s shared voting rights (≈0.12 % of shares) underscore its limited influence on ballots, reducing the likelihood of proposal swings driven by this block alone. Nonetheless, Vanguard’s stewardship policies often press for ESG transparency, which could gradually shape board practices. No red flags emerge regarding attempts to influence control, so governance risk remains neutral.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 9)

Travere Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

89422G107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 89422G107

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 107,100.00
7	Sole Dispositive Power 5,806,026.00
8	Shared Dispositive Power 188,257.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,994,283.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.74 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Travere Therapeutics Inc
(b)	Address of issuer's principal executive offices: 3611 Valley Centre Drive, Suite 300, San Diego, CA, 92130
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 89422G107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5994283
(b)	Percent of class: 6.74 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 107100
	(iii) Sole power to dispose or to direct the disposition of: 5806026
	(iv) Shared power to dispose or to direct the disposition of: 188257
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	07/29/2025

FAQ

How many Travere Therapeutics (TVTX) shares does Vanguard now own?

Vanguard reports 5,994,283 common shares as of 30 Jun 2025.

What percentage of Travere’s outstanding shares does this represent?

The filing lists a stake of 6.74 % of the common stock.

Does Vanguard have voting control over Travere?

No. It has 0 sole voting power and 107,100 shares with shared voting power, indicating minimal voting influence.

Is Vanguard acting as an activist investor in this filing?

No. The certification states the shares were acquired in the ordinary course with no intent to influence control.

Why did Vanguard file Schedule 13G rather than 13D?

Schedule 13G is used for passive ownership above 5 %. Vanguard qualifies as an investment adviser filing under Rule 13d-1(b).